Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr gets tentative approval for generic schizophrenia drug
The company anticipates receiving final approval following the expiration of the 30-month stay in April 2007. The Zyprexa Zydis patent expires on April 23, 2011. Barr’s Abbreviated New
The company anticipates receiving final approval following the expiration of the 30-month stay in April 2007. The Zyprexa Zydis patent expires on April 23, 2011. Barr’s Abbreviated New
The trial will evaluate the safety, pharmacokinetics and pharmacodynamics of GlycoPEG-GCSF versus Neulasta. The phase I trial is designed to evaluate subcutaneous administration of GlycoPEG-GCSF (G-CSF). “We are
In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. Results from the preclinical studies demonstrated that
“Because AN0128 effectively targets inflammation in a topical preparation, it is a promising treatment against atopic dermatitis,” said Dr Karl Beutner, chief medical officer at Anacor. The study
The trial evaluated the effects of mecamylamine taken with citalopram hydrobromide, a treatment combination known as TRIDMAC, in patients who did not respond adequately to citalopram alone. Citalopram
Xcytrin allowed physicians to identify occult brain metastases that are amenable to stereotactic radiosurgery and that were missed with standard MRI contrast agents “These data demonstrate that Xcytrin
The phase I study evaluated patients with advanced solid tumors who had failed prior treatments with a range of anticancer therapies. A total of 43 patients have received
CytoGam is an intravenous immune globulin enriched in antibodies to protect against cytomegalovirus (CMV). It is used to prevent CMV disease associated with transplantation of the kidney, lung,
The milestone payment was triggered by Pharmasset’s successful completion of certain manufacturing activities defined in the hepatitis C virus (HCV) agreement with Roche. This included the development of
High-risk patients include those receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes and hematopoietic stem cell transplant recipients. Invasive fungal infections most often occur in people who